OPRX Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 -15.68%, SMA50 -30.71%, SMA200 -46.08%). The stock’s 14-day RSI is 32.11 (weak momentum), while the ATR of 0.77 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -64.76% below its high and over 96.42% above its low. Average 10-day trading volume of 132.86 thousand shares is below the 3-month average of 302.21 thousand, indicating normal recent market interest.

OptimizeRx Corp. generated EPS of $0.00 over the past year. Five-year average earnings growth is -36.18%. Wall Street analysts project EPS growth of 45.21% annually over the next five years. The latest quarter delivered EPS of $0.16. The next quarter is forecast at $0.22. Next year's EPS is expected at $53.17. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 7 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $32.00 to $7.00. The high target offers 321.05% upside. The low target suggests -7.89% downside. The mean target is $19.00. This offers 150.0% upside. OptimizeRx Corp. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended August 12, 2026, missed forecasts by 44.01%. The prior quarter beat by 1300.0%. Over the last six quarters, Apple has recorded several small beats. These include -172.73% in May 12, 2025.

OptimizeRx Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $6.28. This means the shares are trading above this model’s fair value.

OptimizeRx Corp. has 18.84 million shares outstanding. The public float is 14.50 million shares, elevated short interest at 7.59% of float. This equals 1.36 million shares. The short ratio is 4.71 days. Institutional investors hold 91.61% of the float. Insiders own 12.88%. AWM Investment Company, Inc. holds 1.22 million shares, FEBBO WILLIAM J has 601.25 thousand shares and Lang James Paul has 389.45 thousand shares.

OptimizeRx Corp. (NASDAQ:OPRX) closed at $7.60 USD, losing -$0.27 (-3.43%) from the previous close of $7.87. The stock is currently mid-range between its 52-week high and low $4.54 and $22.25. With a market capitalization of about $142.61 million, OptimizeRx Corp. is classified as a micro-cap and shows market-like volatility (beta ~1.09). Key stats such as the average daily volume over the past year has been around 312.37 thousand shares, volume is running light vs its 52-week average. Headquartered in Waltham, MA, OptimizeRx Corp. operates in the Healthcare sector and the Medical - Healthcare Information Services industry. Led by CEO Stephen L. Silvestro, the company employs approximately 133 people and listed since November 28, 2007. OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers.

OptimizeRx Corp. trades at a P/E ratio of 31.4, slightly below the S&P 500 average, with a price-to-sales ratio of 1.45 and a price-to-book ratio of 1.1 suggesting the stock is closer to book value. The P/FCF stands at 7.82, also above market averages.

OptimizeRx Corp. (NASDAQ:OPRX) shares are flat -2.61% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows OptimizeRx Corp. trading at a premium to the broader market with a P/E of 31.4. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $21.38, suggesting 181.32% upside. Our AI forecast model points to short-term strength (12.89% over two weeks), a medium-term rise (16.45% over three months), and a longer-term loss (-35.26% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that OptimizeRx Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 12.89%, with price expected at $8.58 by September 18, 2026, within a range of $7.99 to $9.16 3-Month Outlook: Projected rise of 16.45%, reaching $8.85 by December 03, 2026, with a range of $8.37 to $9.29. 1-Year Outlook: Projected loss of -35.26%, with price at $4.92 by September 03, 2027, within a range of $0.00 to $2.82.